Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00.Pick ...

PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.

US-Canadian clinical-stage precision oncology company, Repare Therapeutics, has unveiled positive data from its Phase I ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The researchers assessed TROP2 expression in 19 patient samples and found that 52% had high TROP2 expression (H-score ≥100; mean 123.6±90; range, 0-248). A post hoc analysis showed that OS positively ...

Bowel side effects do not differ between patients with localized prostate cancer who receive external beam radiation therapy using protons vs photons, investigators reported in a late-breaking ...